Navigation Links
Helix BioPharma announces Q1 2008 financial results
Date:12/17/2007

d L-DOS47 product candidates continue to be developed.

Operating, general & administration

Operating, general and administration expenses in the first quarter of fiscal 2008 totaled $1,313,000 (2007 - $906,000), for an increase of $407,000. The increase is mainly attributable to a one time charge of $434,000 relating to the resignation of the Company's Chairman.

Amortization of intangible and capital assets

Amortization of intangible assets in the first quarter of fiscal 2008 totaled $7,000 (2007 - $40,000). The variance is due to certain intangible assets which have now been fully amortized. Amortization of capital assets in first quarter of fiscal 2008 totaled $66,000 (2007 - $77,000).

Stock-based compensation

Stock-based compensation expense in the first quarter of fiscal 2008 totalled $12,000 (2007 - $12,000). The stock-based compensation expense relates to the ongoing amortization of compensation costs of stock options granted on June 30, 2005, over their vesting period.

Interest income

Interest income in the first quarter of fiscal 2008 totaled $104,000 and remained flat when compared to the first quarter of fiscal 2007 which totaled $102,000.

Foreign exchange loss

Foreign exchange losses in the first quarter of fiscal 2008 totaled $108,000 (2007 - $45,000). Foreign exchange losses resulting from the foreign currency translation of the Company's integrated foreign operation in Ireland were offset by foreign exchange gains related to the Canadian dollar appreciation versus the U.S. dollar. The Company's net assets in Europe consist mainly of cash and cash equivalents, denominated in Euro currency and are used to fund clinical trials of Topical Interferon Alpha-2b in Europe.

Income taxes

Income tax expense in the first quarter of fiscal 2008 totaled $32,000 (2007 - $29,000). All income taxes are attributable to the Company's operations in Europe.

Other comprehensive income
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
11. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Myriant Corporation, a global ... a distribution agreement with Azelis Group, a specialty ... bio-succinic acid in the Nordics, Benelux, France, Iberia, ... in the industrial and base chemicals markets. , ... a far-reaching chemical portfolio with extensive distribution networks ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... Chief Executive Officer, will present at the Rodman & Renshaw ... New York on Tuesday, Sept. 9, 2014 at ... webcast of the presentation will be accessible by visiting the ... section. About Oncothyreon Oncothyreon ...
(Date:9/2/2014)... -- Spherix Incorporated (SPEX) -- an intellectual property development company committed to ... that the United States Patent & Trademark Office (USPTO) ... of August that are part of a standard essential ... are: , U.S.RE45,065 issued August 5, ... , U.S.RE45,095 issued August 26, 2014.  ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is ... $1,070.7 million in 2014, growing at a CAGR ... oligonucleotide synthesis market is categorized on the basis ... geography. The synthesized oligonucleotides segment is expected to ... synthesis market during the forecast period, owing to ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... , , , SAN ... "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung ... Agents and Chemotherapy (AAC). , , ... clinical development for Influenza-Like Illness. Unlike neuraminidase inhibitors (e.g. Tamiflu ...
... , CAMBRIDGE, Mass., Aug. 25 Peptimmune, ... of a clinical trial to evaluate the safety, tolerability, ... Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel ... other autoimmune diseases. , , The ...
... Medicago Inc. (TSX-V: MDG) a biotechnology company focused ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... Health Canada to commence a Phase I human ... ("H5N1 vaccine"). Enrollment of volunteers is now underway. ...
Cached Biology Technology:NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 2NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 3NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue 4Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 2Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 3Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 2Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine 3
(Date:9/2/2014)... the last decade in Taiyuan, China, have substantially improved ... greater than 50% reduction in costs associated with loss ... to researchers at the Columbia Center for Children,s Environmental ... the Shanxi Medical University, the Center of Diseases Control ... School of Public Health. , The study is the ...
(Date:9/2/2014)... Konservat-Lagersttte of lithographic limestone is well known as ... from that area (for example, Archaeopteryx). Now, for ... in the French equivalent of these outcrops - ... oldest known water treader. , Despite the abundance ... fossils have been obtained from the Late Kimmeridgian ...
(Date:9/2/2014)... people take stress in stride; others are done in ... the molecular mechanisms of this so-called stress gap in ... that could lead researchers to better understand the development ... "Like people, each animal has unique experiences as it ... life experiences can alter the expression of genes, and ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3
... team of Fox Chase Cancer Center scientists led by ... mutation that keeps a mouse strain from developing white ... report by Kappes and his colleagues appears in the ... discovered the mice with this naturally occurring defect in ...
... simian virus 40 produces the Large T antigen which inactivates ... pRb. In a study published in the Journal of Biological ... the discovery of an additional target for T antigen--a protein ... chromosomal region that is deleted in up to 30% of ...
... demonstrated that a gel applied in the vagina provides ... the herpes simplex Virus. The study, presented at the ... first to show that a gel can retain anti-viral ... was funded by the National Institutes of Health (NIH) ...
Cached Biology News:Fox Chase Cancer Center scientists identify immune-system mutation 2New binding target for oncogenic viral protein 2Topical treatment shown to inhibit HIV and herpes simplex virus infection 2
... Osmometer for 10 L sample. Ideal for small volume applications, including pediatric, neonatal, geriatric, general adult, ... in less than 3 minutes after turn-on. ... ... ...
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
Human Jagged 2 Biotinylated Affinity Purified PAb...
Griess Reagent component for determination of nitrite in aqueous solutions....
Biology Products: